Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages.
DNA mismatch repair deficiency
Endometrial cancer
Endometrioid carcinoma
Tumor-associated macrophage
Tumor-infiltrating lymphocyte
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Apr 2022
02 Apr 2022
Historique:
received:
28
09
2021
accepted:
28
02
2022
entrez:
3
4
2022
pubmed:
4
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) may be useful prognostic indicators in endometrial cancer. However, standardized assessment methods and the prognostic roles of these cells in different stage groups are unclear. Formalin-fixed paraffin-embedded tissue samples of 107 endometrioid-type endometrial carcinomas (EECs) comprising 60 stage IB and 47 stage IIIC or IVB cases were evaluated. CD3 By Cox univariate analyses, semiquantitatively low CD3 Both semiquantitatively and quantitatively low E-TILs, are correlated with worse prognosis in both early and advanced stage patients with EECs. In particular, CD3
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) may be useful prognostic indicators in endometrial cancer. However, standardized assessment methods and the prognostic roles of these cells in different stage groups are unclear.
METHODS
METHODS
Formalin-fixed paraffin-embedded tissue samples of 107 endometrioid-type endometrial carcinomas (EECs) comprising 60 stage IB and 47 stage IIIC or IVB cases were evaluated. CD3
RESULTS
RESULTS
By Cox univariate analyses, semiquantitatively low CD3
CONCLUSIONS
CONCLUSIONS
Both semiquantitatively and quantitatively low E-TILs, are correlated with worse prognosis in both early and advanced stage patients with EECs. In particular, CD3
Identifiants
pubmed: 35366828
doi: 10.1186/s12885-022-09363-0
pii: 10.1186/s12885-022-09363-0
pmc: PMC8977032
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361Informations de copyright
© 2022. The Author(s).
Références
Clin Cancer Res. 2019 Apr 15;25(8):2537-2548
pubmed: 30523022
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361
pubmed: 29045681
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Gynecol Oncol. 2008 Apr;109(1):122-8
pubmed: 18289648
Int J Gynecol Cancer. 2015 Sep;25(7):1165-72
pubmed: 26111272
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Cancer. 2014 Dec 15;120(24):3932-9
pubmed: 25081409
Mod Pathol. 2019 Oct;32(10):1536-1543
pubmed: 31175330
Am J Surg Pathol. 2010 Nov;34(11):1708-14
pubmed: 20962622
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gynecol Oncol. 2014 Jul;134(1):20-3
pubmed: 24814467
Dis Markers. 2020 Jan 28;2020:1805764
pubmed: 32076456
Gynecol Oncol. 2009 Jul;114(1):105-10
pubmed: 19411095
Crit Rev Oncol Hematol. 2013 Oct;88(1):154-67
pubmed: 23562498
Clin Cancer Res. 2007 Mar 1;13(5):1472-9
pubmed: 17332291
Gynecol Oncol. 2013 Nov;131(2):309-14
pubmed: 23938375
Oncotarget. 2017 Dec 31;9(5):5652-5664
pubmed: 29464025
Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9
pubmed: 17913510
Anticancer Res. 2014 Oct;34(10):5555-61
pubmed: 25275055
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
Oncology. 1999;57(2):138-42
pubmed: 10461061
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer. 1992 Mar 15;69(6):1424-31
pubmed: 1371712
Ann Surg. 2021 Jul 29;:
pubmed: 34334651
Oncotarget. 2017 Jul 18;8(29):48436-48452
pubmed: 28467800
Hum Pathol. 2008 Jan;39(1):116-25
pubmed: 17949789
Clin Cancer Res. 2004 Jul 1;10(13):4450-6
pubmed: 15240536
Clin Cancer Res. 2008 Apr 15;14(8):2310-7
pubmed: 18413819
Gynecol Oncol. 2014 Nov;135(2):176-83
pubmed: 25173585